To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
How tailored exercise programmes can help people with Parkinson’s
How to find the right Parkinson’s exercise programme
1 month ago
Could a transplant lower the risk of Parkinson’s?
Researchers at Washington University School of Medicine, US, have found that having a heart, kidney, lung or bone marrow transplant could reduce the risk of developing Parkinson’s. As part of the study, published in medical journal ‘Parkinsonism & Related Disorders’, the team assessed data of just under 200,000 patients – 89,790 of whom had Parkinson’s. The results revealed that individuals who had a transplant were 37% less likely to develop Parkinson’s. This could be due to the immunosuppressant medication patients receive before undergoing a transplant, which researchers believe may help slow neurodegeneration as it reduces inflammation in the brain. The study said: “This study provides evidence that tissue transplant may be associated with a lower PD [Parkinson’s disease] risk, warranting further investigation to identify factors that mediate this relationship.”
A breakthrough Parkinson’s trial that featured in a two-part documentary on UK television channel BBC Two has published its results. The study, which featured in the documentary ‘The Parkinson’s Drug Trial: A miracle cure?’, aimed to investigate whether it was possible to restore damaged neurons by administering protein Glial Cell Line Derived Neurotrophic Factor (GDNF). As part of the trial, scientists initially infused GDNF into the brains of six participants living with the condition. Researchers then invited a further 35 individuals with Parkinson’s to take part, with approximately half being administered with a placebo infusion. Although not conclusive, the results suggest that GDNF had an impact on the brain and researchers believe the topic is worthy of further study. Dr Alan Whone, principal investigator on the trial, said: “This represents some of the most compelling evidence yet that we may have a means to possibly reawaken and restore the dopamine brain cells…
Course for Parkinson’s nurses launches in Slovenia
The International Parkinson and Movement Disorder Society is hosting its third summer school for nurses specialising in Parkinson’s. The course – which will be held from 10-12 May in Ljubljana, Slovenia – will focus on the management of the motor and non-motor symptoms of the condition. Students will also attend lectures, examine Parkinson’s patients and discuss treatment plans with experts. All lectures will be presented in English. Heather Vitale, senior programme manager at the International Parkinson and Movement Disorder Society, said: “This course offers a unique opportunity for nurses to enhance their knowledge in Parkinson’s disease, while also learning and networking with their peers through case study presentations and small group discussions.” Registration closes 26 April 2019 and costs USD $350.